Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Depreciation & Amortization (CF) (2016 - 2025)

China Pharma Holdings' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $497425.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 11.01% year-over-year to $497425.0; the TTM value through Dec 2025 reached $1.5 million, down 42.57%, while the annual FY2025 figure was $1.5 million, 42.57% down from the prior year.
  • Depreciation & Amortization (CF) reached $497425.0 in Q4 2025 per CPHI's latest filing, up from $356034.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $976457.0 in Q3 2021 to a low of $320863.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $633185.4, with a median of $689028.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 45.03% in 2021, then tumbled 56.6% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $710716.0 in 2021, then fell by 10.03% to $639425.0 in 2022, then rose by 8.82% to $695835.0 in 2023, then plummeted by 35.61% to $448073.0 in 2024, then increased by 11.01% to $497425.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Depreciation & Amortization (CF) are $497425.0 (Q4 2025), $356034.0 (Q3 2025), and $320863.0 (Q2 2025).